A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Conditions
- Crohn's DiseaseUlcerative Colitis
- Interventions
- Drug: Vedolizumab IVOther: No Intervention
- Registration Number
- NCT05442567
- Lead Sponsor
- Takeda
- Brief Summary
The study is an extension of two parent studies (MLN0002-3024 \[NCT04779307\] and MLN0002-3025 \[NCT04779320\]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.
- Detailed Description
This multi-center trial is conducted worldwide. Up to 240 patients would be enrolled from Studies MLN0002-3024 \[participants with UC\] and MLN0002-3025 \[participants with CD\], either in the Treatment Cohort or in the Observational Cohort. Approximately 93 participants who have previously participated either in study MLN0002-3024 or MLN0002-3025, referred to as parent study, are expected to roll over to the MLN0002-3029 study in the treatment cohort.
Treatment Cohort:
The drug being tested in this study is called vedolizumab, being studied to treat pediatric patients who have UC or CD.
Participants eligible for the Treatment Cohort can be administered vedolizumab intravenous (IV) at Week 54 visit of parent study or up to 1 week after Week 54 of the parent study based on the availability of test results needed to assess eligibility of the participant. At this study entry, participants will be administered the same blinded dose of vedolizumab IV that was received at Week 46 in the parent study and will then continue to receive vedolizumab IV at a frequency of once every 8 weeks (Q8W) in the following treatment groups:
* Participants 10 to ≤15 kilogram (kg), Vedolizumab 150 milligram (mg) (High dose)
* Participants 10 to ≤15 kg, Vedolizumab 100 mg (Low dose)
* Participants \>15 to \<30 kg, Vedolizumab 200 mg (High dose)
* Participants \>15 to \<30 kg, Vedolizumab 100 mg (Low dose)
* Participants ≥30 kg, Vedolizumab 300 mg (High dose)
* Participants ≥30 kg, Vedolizumab 150 mg (Low dose)
Blinding of dose group assignment of the parent study will continue until the final database lock of the parent study in order to protect the blinding of the parent study.
The overall time to participate in the Treatment Cohort of this study is up to participant withdrawal, or until vedolizumab IV is commercially available for pediatric indication(s) in the participant's country or until other drug access programs become available, or Sponsor's decision for study closure, or for up to approximately 5 years, whichever comes first. Participants who complete or are discontinued from the study for any reason will complete the final safety/end of study (EOS) visit 18 weeks after their last dose of study drug.
Observational Cohort:
Participants who received at least 1 dose of study drug during parent study and early terminated or are not eligible for the Treatment Cohort of this study after completion of the Week 54 visit of parent study, will be enrolled in the Observational Cohort of this study as part of a long-term follow-up period to assess prespecified safety events of interest and will not receive continued treatment with vedolizumab IV.
The overall time to participate in the Observational Cohort is up to approximately 2 years.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 240
For Treatment Cohort:
- The participant should have completed Study MLN0002-3024 or Study MLN0002-3025 and achieved corticosteroid-free clinical response at Week 54 (and has tapered off of steroids, as applicable, at least 12 weeks before Week 54) as defined by a reduction of partial Mayo score of ≥2 points and ≥25% from baseline for participants with UC, or by a decrease of pediatric Crohn's disease activity index (PCDAI) of ≥15 points for participants with CD and with total PCDAI ≤30.
- A male participant who is sexually active with a female partner of childbearing potential agrees to use barrier method of contraception (e.g., condom with or without spermicide) from signing of informed consent throughout the duration of the study and for 18 weeks after last dose. The female partner of a male participant should also be advised to use a highly effective method of contraception.
- A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use a highly effective method of contraception from signing of informed consent throughout the duration of the study and 18 weeks after the last dose.
For Observational Cohort:
- The participant has received at least 1 dose of vedolizumab during Study MLN0002-3024 or Study MLN0002-3025 and early terminated OR completed the Week 54 visit of Study MLN0002-3024 or Study MLN0002-3025 but was not eligible to enroll in the treatment cohort of this study.
Main
For Treatment Cohort only:
- The participant currently requires major surgical intervention for UC or CD (e.g., bowel resection), or is anticipated to require major surgical intervention for UC or CD during the study.
- The participant has developed any new unstable or uncontrolled cardiovascular, heart failure moderate to severe (New York Class Association III or IV), pulmonary, hepatic, renal, gastrointestinal (GI), genitourinary, hematological, coagulation, immunological, endocrine/metabolic, neurological, or other medical disorder that, in the opinion of the investigator, would confound the study results or compromise participant safety.
- The participant has other serious comorbidities that will limit their ability to complete the study.
- The participant is unable to comply with all study assessments.
- The participant has hypersensitivity or allergies to any of the vedolizumab excipients.
- The participant is lactating or pregnant.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment Cohort: Participants 10 to ≤15 kg, Vedolizumab 100 mg Vedolizumab IV Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing 10 to ≤15 kg will receive vedolizumab 100 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years. Treatment Cohort: Participants >15 to <30 kg, Vedolizumab 100 mg Vedolizumab IV Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing \>15 to \<30 kg will receive vedolizumab 100 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years. Treatment Cohort: Participants ≥30 kg, Vedolizumab 300 mg Vedolizumab IV Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing ≥30 kg will receive vedolizumab 300 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years. Treatment Cohort: Participants ≥30 kg, Vedolizumab 150 mg Vedolizumab IV Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing ≥30 kg will receive vedolizumab 150 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years. Treatment Cohort: Participants 10 to ≤15 kg, Vedolizumab 150 mg Vedolizumab IV Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing 10 to ≤15 kg will receive vedolizumab 150 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years. Treatment Cohort: Participants >15 to <30 kg, Vedolizumab 200 mg Vedolizumab IV Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing \>15 to \<30 kg will receive vedolizumab 200 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years. Observational Cohort: Early Terminated Participants From Parent Studies No Intervention Participants will have assessment visits at Day 1 and Weeks 8, 34, 60, and 86 as part of a long-term follow-up period to assess prespecified safety events of interest and to monitor growth and pubertal development for approximately 2 years after their last dose of study drug in parent study.
- Primary Outcome Measures
Name Time Method Treatment Cohort: Number of Participants With at Least One Adverse Event (AE) From first dose of study drug up to approximately 5 years An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have causal relationship with this treatment. AE can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug whether or not it is considered related to drug.
Observational Cohort: Number of Participants With Prespecified Safety Events Up to approximately 2 years Prespecified safety events will include serious infections, malignancies, progressive multifocal leukoencephalopathy (PML), concerns about growth and pubertal development, and bowel surgery.
- Secondary Outcome Measures
Name Time Method Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Bowel Symptom Subscale Score for Participants Aged 9 to 17 Years for Every 24 Weeks Baseline, every 24 weeks in this study (up to approximately 5 years) The IMPACT-III Bowel Symptom Subscale is a self-reported measure with 7 closed questions. It uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The bowel symptom subscale score ranges from 1 to 35, with higher scores indicating lesser bowel symptoms. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025.
Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Emotional Functioning Subscale Score for Participants Aged 9 to 17 Years for Every 24 Weeks Baseline, every 24 weeks in this study (up to approximately 5 years) The IMPACT-III Emotional Functioning Subscale is a self-reported measure with 7 closed questions. It uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The emotional functioning subscale score ranges from 1 to 35, with higher scores indicating better emotional functioning. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025.
Treatment Cohort: Time to Major Inflammatory Bowel Disease (IBD)-related Events Up to approximately 5 years Major IBD-related events include hospitalizations, surgeries, and procedures in pediatric participants with UC or CD.
Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Total Score for Participants Aged 9 to 17 Years for Every 24 Weeks Baseline, every 24 weeks in this study (up to approximately 5 years) The IMPACT-III questionnaire is a self-reported measure with 35 closed questions encompassing 6 domains: Bowel Symptoms (7 items), Systemic Symptoms (3 items), Social Functioning (12 items), Body Image (3 items), Treatment/Interventions (3 items), and Emotional Functioning (7 items). The IMPACT-III uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The total score is an average of all item scores. The outcome score ranges from 35 to 175, with higher scores suggesting better quality of life. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025.
Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Systemic Symptom Subscale Score for Participants Aged 9 to 17 Years for Every 24 Weeks Baseline, every 24 weeks in this study (up to approximately 5 years) The IMPACT-III Systemic Symptom Subscale is a self-reported measure with 3 closed questions. It uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The Systemic symptom subscale score ranges from 1 to 15, with higher scores indicating lesser systemic symptoms. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025.
Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Social Functioning Subscale Score for Participants Aged 9 to 17 Years for Every 24 Weeks Baseline, every 24 weeks in this study (up to approximately 5 years) The IMPACT-III Social Functioning Subscale is a self-reported measure with 12 closed questions. It uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The social functioning subscale score ranges from 1 to 60, with higher scores indicating better social functioning. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025.
Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Body Image Subscale Score for Participants Aged 9 to 17 Years for Every 24 Weeks Baseline, every 24 weeks in this study (up to approximately 5 years) The IMPACT-III Body Image Subscale is a self-reported measure with 3 closed questions. It uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The body image subscale score ranges from 1 to 15, with higher scores indicating better body image. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025.
Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Treatment/Intervention Subscale Score for Participants Aged 9 to 17 Years for Every 24 Weeks Baseline, every 24 weeks in this study (up to approximately 5 years) The IMPACT-III Treatment/Intervention Subscale is a self-reported measure with 3 closed questions. It uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The treatment/intervention subscale score ranges from 1 to 15, with higher scores indicating ease of administration of treatment/interventions. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025.
Trial Locations
- Locations (68)
Children's Hospital at Westmead
🇦🇺Westmead, New South Wales, Australia
Goryeb Children's Hospital
🇺🇸Morristown, New Jersey, United States
Texas Children's Hospital
🇺🇸Houston, Texas, United States
Universitair Ziekenhuis Brussel - PIN
🇧🇪Jette, Brussels, Belgium
University of Alberta Hospital
🇨🇦Edmonton, Alberta, Canada
UZ Leuven
🇧🇪Leuven, Vlaams Brabant, Belgium
Fondazione IRCCS San Gerardo dei Tintori - ASST di Monza A. O. San Gerardo
🇮🇹Monza, Lombardia, Italy
Schneider Childrens Medical Center of Israel Petah Tikvah PIN
🇮🇱Petah Tikva, HaMerkaz, Israel
Queensland Childrens Hospital
🇦🇺South Brisbane, Queensland, Australia
Samsung Medical Center - PPDS
🇰🇷Seoul, Korea, Republic of
Hadassah Medical Center - PPDS
🇮🇱Jerusalem, Yerushalayim, Israel
MNGI Digestive Health PA-Plymouth
🇺🇸Minneapolis, Minnesota, United States
Monash Health, Monash Medical Centre
🇦🇺Clayton, Victoria, Australia
Uniwersytecki Szpital Dzieciecy
🇵🇱Krakow, Malopolskie, Poland
Gachon University Gil Medical Center
🇰🇷Incheon, Incheon Gwang'yeogsi, Korea, Republic of
Instytut Pomnik Centrum Zdrowia Dziecka
🇵🇱Warszawa, Mazowieckie, Poland
Semmelweis Egyetem
🇭🇺Budapest, Hungary
Japanese Red Cross Kumamoto Hospital
🇯🇵Kumamoto-shi, Kumamoto, Japan
Royal Children's Hospital Melbourne - PIN
🇦🇺Parkville, Victoria, Australia
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Korczowski Bartosz, Gabinet Lekarski
🇵🇱Rzeszow, Podkarpackie, Poland
Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktato Korhaz
🇭🇺Miskolc, Borsod-Abauj-Zemplen, Hungary
Rambam Medical Center - PPDS
🇮🇱Haifa, Israel
Instytut Centrum Zdrowia Matki Polki
🇵🇱Lodz, Lodzkie, Poland
Royal Manchester Children's Hospital - PPDS
🇬🇧Manchester, United Kingdom
Universita degli Studi di Padova
🇮🇹Padova, Veneto, Italy
Kyungpook National University Chilgok hospital
🇰🇷Daegu, Daegu Gwang'yeogsi, Korea, Republic of
Great Ormond Street Hospital (GOSH)
🇬🇧London, London, City Of, United Kingdom
WIP Warsaw IBD Point Profesor Kierkus
🇵🇱Warszawa, Mazowieckie, Poland
Noahs Ark Childrens Hospital for Wales - PPDS - PIN
🇬🇧Cardiff, South Glamorgan, United Kingdom
Johns Hopkins University
🇺🇸Baltimore, Maryland, United States
Childrens Center For Digestive Healthcare
🇺🇸Atlanta, Georgia, United States
Advocate Children's Hospital Park Ridge
🇺🇸Park Ridge, Illinois, United States
Boston Children's Hospital
🇺🇸Boston, Massachusetts, United States
University Hospitals Cleveland Medical Center
🇺🇸Cleveland, Ohio, United States
Children's Hospital of Pittsburgh
🇺🇸Pittsburgh, Pennsylvania, United States
AOU dell'Universita degli Studi della Campania Luigi Vanvitelli
🇮🇹Napoli, Campania, Italy
Azienda Ospedaliera Universitaria Federico II
🇮🇹Napoli, Campania, Italy
Attikon University General Hospital
🇬🇷Athens, Attiki, Greece
Children's Hospital "Agia Sofia"
🇬🇷Athens, Greece
Ippokratio General Hospital of Thessaloniki
🇬🇷Thessaloniki, Greece
Beijing Children Hospital,Capital Medical University
🇨🇳Beijing, Beijing, China
Henan Children's Hospital (Zhengzhou Children's Hospital)
🇨🇳Zhengzhou, Henan, China
The Children's Hospital Zhejiang UniversitySchool of Medicine
🇨🇳Hangzhou, Zhejiang, China
Children's Hospital of Fudan University
🇨🇳Shanghai, Shanghai, China
Azienda USL di Bologna
🇮🇹Bologna, Emilia-Romagna, Italy
London Health Sciences Centre
🇨🇦London, Ontario, Canada
Kurume University Hospital
🇯🇵Kurume-Shi, Hukuoka, Japan
Barts Health NHS Trust
🇬🇧London, United Kingdom
Tel Aviv Sourasky Medical Center PPDS
🇮🇱Tel-Aviv, Israel
Phoenix Childrens Hospital -1919 E Thompson Rd
🇺🇸Phoenix, Arizona, United States
Rady Childrens Hospital San Diego - PIN
🇺🇸San Diego, California, United States
Mayo Clinic - PIN
🇺🇸Rochester, Minnesota, United States
Carilion Children's Tanglewood Center
🇺🇸Roanoke, Virginia, United States
UZ Antwerpen
🇧🇪Edegem, Antwerpen, Belgium
Carmel Medical Center
🇮🇱Haifa, Israel
Shaare Zedek Medical Center
🇮🇱Jerusalem, Israel
Juntendo University Hospital
🇯🇵Bunkyo-Ku, Tokyo, Japan
SPZOZ Centralny Szpital Kliniczny UM w Lodzi
🇵🇱Lodz, Poland
Twoja Przychodnia SCM
🇵🇱Szczecin, Zachodniopomorskie, Poland
Gornoslaskie Centrum Zdrowia Dziecka Im. Sw. Jana Pawla II Spsk Nr 6 Sum W Katowicach
🇵🇱Katowice, Slaskie, Poland
Narodny ustav detskych chorob
🇸🇰Bratislava, Slovakia
Birmingham Children's Hospital NHS Foundation Trust
🇬🇧Birmingham, West Midlands, United Kingdom
The Steven and Alexandra Cohen Childrens Medical Center of New York - BRANY - PPDS
🇺🇸New Hyde Park, New York, United States
National Center for Child Health and Development
🇯🇵Setagaya-Ku, Tokyo, Japan
British Columbia Children's Hospital
🇨🇦Vancouver, British Columbia, Canada
Sapienza University of Rome
🇮🇹Roma, Lazio, Italy
Klinika Za Djecje Bolesti Zagreb
🇭🇷Zagreb, Grad Zagreb, Croatia